



Evripidis Gavathiotis

Dr. Evripidis Gavathiotis is a Professor of Biochemistry, Medicine and Oncology at Albert Einstein College of Medicine and Co-Leader of the Cancer Therapeutics Program at Montefiore Einstein Comprehensive Cancer Center. He received his B.Sc. in chemistry at the University of Crete, Greece and his Ph.D. in biological chemistry from the University of Nottingham, UK. He completed postdoctoral research in structural and chemical biology at Rockefeller University and at Dana-Farber Cancer Institute and he was junior faculty at Harvard Medical School. He joined Albert Einstein College of Medicine in 2011 as Assistant Professor and became tenured Full Professor in 2019. His research focuses on investigation of cell death mechanisms for the development of therapeutic strategies and prototype therapeutic small molecules for the treatment of various cancers and other diseases. Dr. Gavathiotis has pioneered mechanistic insights of key cell death proteins, elucidated novel targets for mitochondrial apoptosis, mitochondrial dynamics, chaperone-mediated autophagy, senescence and MAPK/ERK signaling and discovered first-in-class small molecules for several challenging targets that developed into clinical candidates. Dr. Gavathiotis has co-authored numerous publications in high-impact journals and he has more than 40 United States-issued patents and patent applications. He has been honored with numerous awards including the Sidney Kimmel Scholar Award, the Young Chemical Biologist Award, the Pershing Square Sohn Prize and the Irma T. Hirsch Career Scientist Award. He has served on multiple NIH study sections and science advisory boards and has co-founded three biotechnology companies based on discoveries from his laboratory.